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Abstract
Background: Pulmonary nocardiosis frequently occurs in immunocompromised hosts and in some immunocompetent
hosts with chronic lung disease; however, few reports have described pulmonary nocardiosis with nontuberculous
mycobacterial lung infection. Here we report for the first time two cases of pulmonary nocardiosis caused by Nocardia
cyriacigeorgica associated with Mycobacterium avium complex (MAC) lung disease caused by M. avium.
Case presentation: Case 1 is that of a 72-year-old Japanese man with untreated MAC lung disease, who was diagnosed
with rheumatoid arthritis and initiated on methotrexate. After 3 years of methotrexate therapy, the patient remained
smear-negative and culture-positive for MAC, but also became smear-positive for Nocardia species. He received
trimethoprim/sulfamethoxazole, and his symptoms and lung infiltrates improved. Case 2 is that of an immunocompetent
53-year-old Japanese woman with MAC lung disease, who was treated with a combined therapy of clarithromycin,
rifampicin, ethambutol, and levofloxacin. MAC sputum culture was negative after 1 year of combined treatment, which
was maintained for 2 years. After four treatment-free years, Nocardia species were occasionally isolated from her
sputum, although MAC was rarely isolated from sputum cultures over the same period. In both cases, the Nocardia
species were identified as the recently defined N. cyriacigeorgica by 16S ribosomal RNA gene sequencing.
Conclusion: We report two cases of pulmonary nocardiosis caused by N. cyriacigeorgica associated with MAC lung
disease caused by M. avium and suggest that N. cyriacigeorgica may be a major infective agent associated with MAC
lung disease.
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Background
Pulmonary nocardiosis is an uncommon pulmonary in-
fection caused by aerobic gram-positive actinomycetes
of the genus Nocardia [1]. It occurs mainly as an oppor-
tunistic infection in immunocompromised patients, par-
ticularly in those with defects in cell-mediated immunity
such as patients with human immunodeficiency virus
(HIV) infection and those receiving long-term systemic
steroids or immunosuppressive agents; however, it can
also affect immunocompetent hosts with no underlying
disease [2-6]. Pulmonary nocardiosis often occurs with
chronic lung diseases such as chronic obstructive pulmon-
ary disease (COPD) and bronchiectasis [2-4].
Mycobacterium avium complex (MAC) lung disease is
becoming more prevalent [7]. It often occurs in immuno-
compromised hosts such as patients with HIV and in
immunocompetent hosts with chronic lung diseases such
as COPD and bronchiectasis; however, around 20% of
MAC patients have no underlying disease [8]. A subset
of patients with MAC lung disease may also experience
pulmonary nocardiosis. Previous reports have described
a case of pulmonary Nocardia farcinica infection in a
patient with Mycobacterium intracellulare infection and
bronchiectasis [9] and a case of pulmonary Nocardia
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asteroides infection in a patient with MAC infection,
following allogeneic bone marrow transplantation [10].
Co-infection with N. asteroides and MAC has also been
reported in a patient with AIDS [11]. Another report
described a case of empyema caused by Mycobacterium
tuberculosis, Nontuberculous mycobacteria (species not
identified), and N. asteroides isolated from pleural effusion
in a middle-aged woman with systemic lupus erythemato-
sus, treated with long-term corticosteroids [12]. There has
been no similar report of pulmonary nocardiosis caused
by Nocardia cyriacigeorgica in patients with MAC lung
disease.
To the best of our knowledge, this is the first report of
two cases of pulmonary N. cyriacigeorgica infection with
MAC lung disease caused by M. avium, including an im-
munocompromised 72-year-old man with rheumatoid
arthritis (RA), treated with methotrexate for several
years (Case 1), and an immunocompetent 53-year-old
woman (Case 2).
Case presentation
Case 1 is that of a 72-year-old Japanese man with
untreated MAC lung disease caused by M. avium, which
was followed 2 years later with a clinical diagnosis of
RA; he was referred to a university hospital in 2009.
Treatment with methotrexate was initiated for high RA
disease activity. Although MAC was continuously isolated
from his sputum, he was carefully followed without med-
ical treatment because smear tests were negative, he had
no respiratory symptoms, and lung infiltrates were stable.
After 3 years of methotrexate therapy, Nocardia species
appeared and were continuously isolated from his sputum,
which was smear-negative but culture-positive for MAC.
His sputum amount increased and chest X-ray imaging
and computed tomography (CT) revealed exacerbation
of infiltrates in the upper lobes on both sides and in the
right middle lobe of the lungs (Figure 1A and B). He
had no smoking history and neither cutaneous nor cen-
tral nervous system nocardiosis. His laboratory findings
were almost normal, including normal interferon-gamma
release assays (IGRA), with the exception of a high titer
of anti-tuberculous glycolipid (TBGL) antigen antibody
(19.0 U/mL) and anti-glycopeptidolipid (GPL) core anti-
gen immunoglobulin A (IgA) antibody (4.6 U/mL). He
started receiving treatment with trimethoprim/sulfameth-
oxazole (TMP/SMX) in August 2012. His symptoms
and the infiltrates improved after 3 months of therapy
(Figure 1C and D).
Case 2 is that of a 53-year-old Japanese woman referred
to a university hospital as an outpatient because of an
abnormal shadow upon chest X-ray imaging in 2001. She
was a former smoker with a 6-pack-year smoking history
(4 cigarettes per day for 30 years). The forced expiratory
volume in 1 second/forced vital capacity (FEV1/FVC) ratio
was slightly decreased (68.7%). Since her sputum smear
and culture were positive for MAC and chest CT revealed
widespread bilateral nodular bronchiectatic pulmonary
infiltrates, she was initiated on combined therapy with
clarithromycin (400 mg/day), rifampicin (600 mg/day),
ethambutol (1000 mg/day), and levofloxacin (400 mg/
day) shortly after diagnosis in 2001. The sputum MAC
culture turned negative 1 year after initiating therapy
and she completed 2 years of treatment in 2003. After
four treatment-free years, Nocardia species appeared in
her sputum in 2007. We continued careful follow-up
without medical treatment because she was immuno-
competent and showed no symptoms except for a very
mild cough; her sputum culture was often negative for
Nocardia species and lung infiltrates were stable. Chest
X-ray imaging and CT in 2013 revealed an exacerbation
of infiltrates in the right middle lobe, a small cavity in
the right lower lobe, and centrilobular nodules in the left
upper lobe of the lungs (Figure 2C and D) in comparison
to images obtained 15 months before exacerbation of the
Figure 1 Chest X-ray and chest computed tomography (CT)
findings in Case 1. Chest X-ray and chest CT findings examined at
the time of therapeutic initiation with trimethoprim-sulfamethoxazole
(A and B) and after three months of therapy (C and D).
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infiltrates (Figure 2A and B). She was admitted to the
University Hospital for bronchoscopy. Her physical exam-
ination was unremarkable and she had neither cutaneous
nor central nervous system nocardiosis. Her laboratory
findings were almost normal, including normal IGRA,
except for a high titer of anti-TBGL antigen antibody
(9.9 U/mL) and anti-GPL core antigen IgA antibody
(>10.00 U/mL). Bronchial washing, bronchial curettage,
and transbronchial lung biopsy through right B5 and B6
were performed. Nocardia species but not MAC were
cultured from samples of the bronchial wash. The patho-
gen responsible for the exacerbated infiltrates on chest CT
was accordingly considered to be Nocardia. The patient is
being followed closely; the decision to treat for Nocardia
remains pending a change in her status.
In both cases, Nocardia species isolated from sputum
were identified as N. cyriacigeorgica by 16S ribosomal
RNA gene sequencing. Table 1 shows the minimum
inhibitory concentration (MIC) of the indicated antibiotics
against N. cyriacigeorgica in each case. Susceptibility test-
ing was performed according to Clinical and Laboratory
Standards Institute (CLSI) document M24-A [13]; the spe-
cific susceptible breakpoint of TMP/SMX for Nocardia
species was ≤2/38 and the specific resistance breakpoint
was ≥4/76. The MICs of TMP/SMX for N. cyriacigeorgica
were 0.5/9.5 in Case 1 and 8/152 in Case 2. Thus, the N.
cyriacigeorgica isolate in Case 1 was regarded as sensitive
to TMP/SMX, while the isolate in Case 2 was regarded as
resistant.
Discussion
Pulmonary nocardiosis is the most frequent presentation
of infection by Nocardia species [1], associated with op-
portunistic infections in immunocompromised hosts, par-
ticularly in those with impaired cell-mediated immunity,
although immunocompetent hosts can also present with
pulmonary nocardiosis. In spite of the fact that Nocardia
infection is relatively rare, early diagnosis and treatment is
important because of its poor prognosis in selected cases.
A few reports have described pulmonary nocardiosis in
patients with nontuberculous mycobacterial lung infection
[9-12]. Here, we report two cases of pulmonary N. cyriaci-
georgica infection in patients with MAC lung disease.
Accumulating evidence suggests there are defined risk
factors for Nocardia species infection: HIV infection [5],
corticosteroid therapy or use of immunosuppressive agents
[5,6], organ transplantation [6], and diabetes mellitus [3].
Preexisting rheumatic disease treated with immunosup-
pressant therapy, as in Case 1, is another risk factor for
Nocardia species infection [14]. Preexisting pulmonary
diseases such as COPD and bronchiectasis are additional
risk factors for pulmonary nocardiosis, which occur when
bacterial colonization in the lower respiratory tract alters
ciliary motility and causes epithelial damage [4]. It is un-
clear whether preexisting nontuberculous mycobacterium
Figure 2 Chest X-ray and chest computed tomography (CT)
findings in Case 2. Chest X-ray and chest CT findings 15 months
before the exacerbation of lung infiltrates (A and B) and at the time
of exacerbation (C and D).
Table 1 Antimicrobial susceptibilities of Nocardia
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is an independent risk factor for pulmonary nocardiosis,
although colonization in the lower respiratory tract may
also alter ciliary motility and cause epithelial damage as
well as COPD and bronchiectasis. Intrinsic defects in
airway clearance may also contribute to the susceptibility
to pulmonary nontuberculous mycobacterial infection and
nocardiosis. Indeed, a previous report demonstrated that
mutations in the cystic fibrosis transmembrane regulator
likely contribute to susceptibility and pathogenesis in
adults with bronchiectasis and pulmonary nontuberculous
mycobacterial infection [15]. Airway clearance therapies
are likely to function in synergy with antimicrobial therapy
to accelerate resolution of airway infections. In Case 2, the
patient had a long-term history of smoking (4 cigarettes
per day for 30 years) and the FEV1/FVC ratio was slightly
reduced at the initial visit. Although chest CT did not
show pulmonary emphysema, she may have a chronic
bronchitis form of mild COPD and mild bronchiectasis.
Preexisting COPD, bronchiectasis, and MAC lung disease
may contribute to the co-infection with Nocardia in
Case 2.
The Nocardia species isolated from our patients was N.
cyriacigeorgica, a recently identified species confirmed by
16S ribosomal RNA gene sequencing. N. cyriacigeorgica
was first classified in 2001 by Yassin et al. as a novel spe-
cies distinguished by molecular and biochemical analysis
from previously identified members of the genus Nocardia
such as N. asteroides [16]. A recent study showed that
a quarter of the strains from Japan and Thailand that
were identified as N. asteroides in fact belonged to N.
cyriacigeorgica (27 of 121 cases) [17]. In addition, N.
cyriacigeorgica is the most frequently isolated strain in
Taiwanese patients with pulmonary nocardiosis (10 of 20
cases) [18]. N. cyriacigeorgica infection may be most
common in East and Southeast Asia. Larger populations
should be studied to improve our understanding of the
characteristics of pulmonary N. cyriacigeorgica infection.
Nocardia species co-infection may be underestimated in
patients with MAC lung disease because Nocardia and
MAC infection often develop in immunocompromised
hosts and in selected immunocompetent hosts with
chronic lung disease. Chest CT findings in MAC lung
disease, such as nodular bronchiectatic lesions, often
resemble those in Nocardia species infection; thus, clini-
cians may not suspect the relatively rare Nocardia species
co-infection. Nocardia species also grow slowly and
positive cultures may take up to 4 weeks to appear; thus,
clinicians may not obtain positive culture results for
Nocardia species unless they proactively suspect Nocardia
infection and incubate the samples for longer than
normal.
TMP/SMX is widely used in first-line therapy of pulmon-
ary nocardiosis. Amikacin, imipenem, third-generation
cephalosporins, minocycline, netilmicin, and amoxicillin-
clavulanic acid are also effective against Nocardia isolates
in vitro and can be used as alternative antimicrobial agents
[4]. However, no randomized prospective controlled trials
have been performed to determine the most appropriate
therapeutic agent, route of administration, and treatment
duration for patients with pulmonary nocardiosis [2]. N.
cyriacigeorgica isolated in Case 2 was resistant to TMP/
SMX, according to the CLSI definition of susceptibility.
TMP/SMX may be excluded as a candidate drug for
treatment of pulmonary nocardiosis in Case 2. However,
susceptibility test results do not always correlate with
clinical outcomes of treatment for Nocardia [19]. In fact, a
favorable response was reported in 3 of 4 cases (75%) with
TMP/SMX-resistant strains [19]. Therefore, TMP/SMX
remains a candidate antimicrobial agent to treat pulmon-
ary nocardiosis in Case 2.
Conclusions
This is the first report of pulmonary nocardiosis due to
N. cyriacigeorgica in patients with MAC lung disease.
Nocardia species co-infection may be underestimated in
patients with MAC lung disease and N. cyriacigeorgica
may be the main Nocardia species co-incident with MAC
lung disease.
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